PT  - JOURNAL ARTICLE
AU  - Magalhães, Claudia Saad
AU  - Suppo de Souza Rugolo, Ligia Maria
AU  - Trindade, Cleide Enoir Petean
TI  - Neonatal Antiphospholipid Syndrome
AID  - 10.1542/neo.15-5-e169
DP  - 2014 May 01
TA  - NeoReviews
PG  - e169--e176
VI  - 15
IP  - 5
4099  - http://neoreviews.aappublications.org/content/15/5/e169.short
4100  - http://neoreviews.aappublications.org/content/15/5/e169.full
SO  - NeoReviews2014 May 01; 15
AB  - Abbreviations:AID, autoimmune diseasesAPS, antiphospholipid antibody syndromeaPLs, antiphospholipid antibodiesaCLs, anticardiolipin antibodiesCAPS, catastrophic antiphospholipid antibody syndromeGP-I, anti-β-2 glycoprotein I antibodiesHLA, histocompatibility leukocyte antigenIg, immunoglobulinLA, lupus anticoagulantSLE, systemic lupus erythematosusAntiphospholipid antibody syndrome (APS) during pregnancy may result in pregnancy morbidity and passive transfer of antibodies to the fetus, resulting in an increased risk of prematurity, intrauterine growth restriction, thrombocytopenia, and developmental delay. Antiphospholipid antibodies may have an impact on neurodevelopment during fetal life. Although rare, persistence of these antibodies in the neonate may lead to thromboembolism, particularly if there is a concurrent infection and/or inherited thrombophilic disorders. Affected pregnant women need to be identified early during gestation so that they can have close monitoring of the placental circulation, fetal growth and development, and testing of serum antiphospholipid antibody levels. Neonates born to mothers with antiphospholipid antibody syndrome should have close neurodevelopment follow-up.